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Hypertension is the common adverse event associated with vascular endothelial growth factor 
receptor-tyrosine kinase inhibitors. The present study was performed to identify the predictive 
factor(s) of tyrosine kinase inhibitor-induced hypertension and to determine the classes of 
antihypertensive agents that show the best efficacy against this hypertension. We retrospectively 
examined charts of 50 cases with vascular endothelial growth factor receptor-tyrosine kinase 
inhibitor treatment. The relation between backgrounds and tyrosine kinase inhibitor-induced 
hypertension and effect of antihypertensive agents administered were analyzed. High systolic 
blood pressure at baseline was a predictive factor for hypertension. There was no difference 
between calcium channel blockers and angiotensin receptor II blockers as first-line 
antihypertensive agents for control of the hypertension. Our findings may be helpful for predicting 
the onset of tyrosine kinase inhibitor-induced hypertension and for management with primary use 





It had been suggested that antitumor agents do not have a beneficial effect on patient survival in 
cases of kidney cancer. Only cytokine therapies, such as interferon alpha and interleukin-2, have 
been used for metastatic or surgically unresectable kidney cancer (MKC) patients. However, 
these agents show insufficient efficacy [1-3]. Since the phase III trial investigating the effects of 
sorafenib on MKC, vascular endothelial growth factor (VEGF) signaling pathway inhibitors 
emerged as leading treatments for MKC [4-8]. Three VEGF receptor-tyrosine kinase inhibitors 
(VEGFR-TKI), i.e, sorafenib, sunitinib, and axitinib, are available for MKC in Japan as of 2012. 
The affinity and selectivity of VEGFR-TKI for VEGFR are different, and accordingly the incidence 
and severity of adverse events (AE) are also different [5-7]. Hypertension (HT) is the most 
common AE associated with VEGFR-TKI, and it sometimes becomes a critical factor of 
discontinuation of VEGFR-TKI [5-8]. On the other hand, the onset of HT after initiation of 
VEGFR-TKI was reported as a possible biomarker of good response to VEGFR-TKI [9]. Therefore, 
the control of HT is very important for continuation of VEGFR-TKI and to achieve the best 
outcome in MKC treatment. The present study was performed to identify the predictive factor(s) of 
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VEGFR-TKI-induced HT, and to determine the classes of antihypertensive agents (AHTA) that 
show the best efficacy against this secondary HT. 
  
5 
Patients and Methods 
 
Study population 
All studies were performed retrospectively in Kanazawa University using charts of patients who 
were hospitalized at the Department of Urology. MKC patients who underwent VEGFR-TKI 
(sorafenib, sunitinib, and axitinib) therapy were analyzed. The AHTA administered were 
categorized according to their mechanisms of action. 
 
Definition of HT 
HT was defined as systolic blood pressure (BP) > 140 mmHg corresponding to Grade 2 of the 
National Cancer Institute-Common Terminology Criteria for Adverse Events version 4.0. Our 
department policy of starting AHTA administration was also the same as the definition of HT. BP of 
all cases was reviewed before VEGFR-TKI administration (baseline), between the onset of de 
novo HT and starting AHTA administration, and when the HT improved after AHTA administration. 
The average BP levels at identical times on 3 consecutive days were calculated and used for 






Statistical analyses were performed using commercially available software (Prism). Comparisons 
between two groups were performed by unpaired two-sided t test, Fisher’s exact test, and 
chi-square test for trends. The probability of administration of AHTA was estimated using the 






Fifty VEGFR-TKI administration events from 41 patients could be analyzed. Patient demographic 
data are shown in Table 1.The numbers of cases of sorafenib, sunitinib, and axitinib 
administration were 18, 27, and 5, respectively. Twenty-two patients had preexisting HT and one 
or two AHTA had already been prescribed. The possibility of AHTA administration is shown in Fig. 
1a. 
 
Predictive factor of VEGFR-TKI-induced HT 
Of 50 cases, 20 had HT after VEGFR-TKI administration, and their backgrounds were compared 
with those of 30 non-HT cases (Table 2). Median systolic BP at baseline was significantly high in 
20 HT cases, and the distributions of systolic BP in the non-HT and HT groups are shown in Fig. 
1b. Two had Grade 2 HT at baseline and started AHTA after deterioration of HT to Grade 3 
(systolic BP > 160 mmHg). The distributions of BP at baseline and before AHTA administration in 




Usage of AHTA 
The differences in efficacy among AHTA administered in 13 cases of de novo HT, i.e., with no 
AHTA administration before initiation of VEGFR-TKI, were analyzed. First-line AHTA was either 
calcium channel blockers (CCB) or angiotensin receptor II blockers (ARB). There was no 
significant difference between control rate of CCB and ARB as first-line treatment (3 of 8 in CCB 






It is important to identify predictive factors for key AE associated with VEGF-TKI to prevent 
discontinuation and to predict the population likely to show a good response to these agents. 
Moreover, it may contribute to better outcome. In axitinib treatment for Japanese MKC patients, 
Tomita et al. suggested that baseline proteinuria and soluble VEGFR-2 levels may be predictive 
factors of axitinib-induced proteinuria, which may also be a predictive factor of good response to 
axitinib [10]. With regard to HT, a study of the VEGFR-TKI cediranib for non-small cell lung cancer 
indicated that predictors of VEGFR-TKI-induced HT were Eastern Cooperative Oncology Group 
performance status 0, female, normal LDH, and no prior peripheral vascular disease [11]. A 
meta-analysis of sunitinib indicated a significantly higher incidence of sunitinib-induced HT in 
MKC than gastrointestinal stromal tumors [12]. These studies indicated that predictors of 
VEGFR-TKI-induced HT in MKC patients should exist, and should be identified for extended 
VEGFR-TKI use in MKC. In the present study, high baseline systolic BP was the only predictive 
factor for VEGFR-TKI-induced HT. This result is reasonable, and indicated that evaluation of BP 
at baseline is important for management of VEGFR-TKI administration. As there is still 
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controversy regarding the optimal treatment for VEGFR-TKI-induced HT, we investigated which 
category of AHTA is preferable for treatment of secondary HT based on the charts of 13 de novo 
HT cases. As expected, two major categories of AHTA were used as first-line therapy for 
VEGFR-TKI-induced HT, i.e., CCB and ARB, and there was no difference in efficacy between 
these two AHTA categories. Although some review articles proposed usage of AHTA for 
VEGFR-TKI-induced HT, there is no evidence that the specific usage of AHTA should be applied 
for VEGFR-TKI-induced HT [13-15]. However, the unique situation of VEGFR-TKI-induced HT 
should be taken into consideration. It has been reported that ARB may have antitumor effects 
through the inhibition of angiotensin II signaling [16]. A systematic review indicated that ARB 
could improve progression-free survival in MKC patients, and that ARB administration was 
protective against prostate specific antigen failure in prostate cancer patients [17]. Moreover, ARB 
could decrease pressure in the glomerulus, and then reduce proteinuria, consequently inhibiting 
the deterioration of renal function [18, 19]. As proteinuria is a critical AE of VEGFR-TKI as well as 
HT [7, 10],  ARB may be preferable for patients treated with VEGFR-TKI. On the other hand, ARB 
cannot be used for patients with bilateral renal artery stenoses or solitary kidney associated with 
renal artery stenosis, or for patients with elevated creatinine level > 2.0 mg/dL, and CCB may be 
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appropriate in such cases. Although this was a retrospective study with a small sample size, we 
showed that baseline BP may predict VEGFR-TKI-induced HT, and that there is no difference in 
efficacy for VEGFR-TKI-induced HT between CCB and ARB. Our findings may be helpful for 
clinicians to predict the onset of VEGFR-TKI-induced HT and for management with primary use of 
either CCB or ARB.  
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Table 1. Patient demographics 
n  50 
Median age, yr  65 (26 – 85) 
Gender male 43 
 female 7 
Prior nephrectomy yes 30 
 no 20 
TKI sorafenib 18 
 sunitinib 27 
 axitinib 5 
Median TKI administration days 102 (7 – 1117) 
Median initial BP systolic 116 (96 – 157) 
 diastolic 72 (57 – 90) 
Number of prior AHTA 0 28 
 1 13 
 2 9 




 ACEI 1 
 others 4 
TKI-induced HT yes 20 
  no 30 
ACEI = angiotensin converting enzyme inhibitors. Values in parentheses 
indicate range. 
†





Table 2. Comparison of backgrounds between HT and non-HT patients 
  no HT HT P 
n  30 20  
Median age, yr  65 (26 – 80) 66 (47 – 85) 0.5992 
Gender male 26 17 1 
 female 4 3  
Prior nephrectomy yes 17 13 0.7688 
 no 13 7  
TKI sorafenib 11 7 0.9923 
 sunitinib 16 11  
 axitinib 3 2  
Median TKI administration days 69 (5 – 1047) 188 (21 – 1117) 0.1895 
Median initial BP systolic 114 (96 – 133) 122 (104 – 157) 0.0104 
 diastolic 70 (58 – 83) 74 (57 – 90) 0.2555 
Number of prior AHTA 0 15 13 0.3486 
 1 10 3  
 2 5 4  
Administered AHTA CCB 13 4 0.3127 
 ARB 5
†
 4  
 ACEI 0 1  
  Others 2 2   
Values in parentheses indicate range.
 †
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 Figure legends 
 
Fig. 1 The possibility of AHTA administration is shown using the Kaplan–Meier method (a). 
Average systolic BP at baseline in non-HT (n = 30) and HT (n = 20) groups are shown (b). 
Average systolic and diastolic BP at baseline and before AHTA administration in the HT group are 
shown (c). 
 
Fig. 2 AHTA administered for EGFR-TKI-induced de novo HT are shown. Either CCB or ARB was 
administered for de novo HT as first-line therapy, and second- and third-line AHTA were added if 
necessary. 
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